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1	  Abstract	  
	   1.1	  English	  	  
Mitogens are substances capable of inducing cell proliferation. Upon binding 
to their receptors a signal pathway is activated resulting in gene transcription 
and cell proliferation. These signals are usually carefully regulated, but cancer 
cells lack this regulation and the result is uncontrolled cell division. Breast 
cancer is the most common cancer among women in the western world. 
Several subtypes are involved depending on which receptor is overexpressed, 
each type with its own expression, treatment and prognosis. FoxA1 is a 
protein functioning as a pioneer factor due to its chromatin remodeling ability, 
so receptors like estrogen receptor can bind to estrogen responsive elements 
(ERE) on the DNA and start transcription of estrogen target genes. The 
treatment of breast cancer depends on the subtype, but the women do not 
always respond to treatment without a clear reason. Due to this, it is 
interesting to explore if the hormones, like estrogen and androgen, or growth 
factors, like heregulin and epidermal growth factor, are independently able to 
remodel the chromatin or if the presence of FoxA1 is necessary. This project 
was conducted with a method called FAIRE, which isolates the nucleosome 
free DNA, the part of DNA supposedly active during transcription. When the 
DNA is not being transcribed it is densely packed in nucleosomes. The results 
show that growth factors are able to open several regions while the hormones 
are more active in closing them. All the hormones and growth factors are 
more or less affected by FoxA1. 	  
	   1.2	  Norwegian	  
 
Mitogener er substanser som har evne til å indusere celledeling. Når disse 
bindes sine respektive reseptorer starter en kaskade av cellulære signaler 
som kan ende i nukleus med transkripsjon av gener og celledeling. Disse 
signalene er vanligvis nøye regulert, men i kreftceller virker ikke denne 
reguleringen og resultatet er ukontrollert cellevekst. Brystkreft er den vanligste 
kreftformen blant kvinner i den vestlige verden. Det finnes flere ulike subtyper 
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brystkreft, avhengig av hvilke reseptorer som er uttrykt, hver med sitt 
sykdomsbilde, behandling og prognose. FoxA1 er et protein som fungerer 
som en pionerfaktor, med sin evne til å åpne kromatinet slik at eksempelvis 
østrogenreseptor kan binde seg til østrogen responsivt element (ERE) på 
DNA'et og starte transkripsjon av østrogen mål-gener. Det er ulike måter å 
behandle brystkreft på, avhengig av typen, men det er ikke alltid behandlingen 
virker uten at man forstår hvorfor. Det er derfor spennende å se om hormoner 
som østrogen eller androgen, eller vekstfaktorer som heregulin eller 
epidermale vekst faktorer kan åpne kromatinet på egenhånd eller om det er 
avhengig av FoxA1. Dette prosjektet ble utført med en metode som heter 
FAIRE, som isolerer nukleosomfritt DNA, den delen av DNA som antas å 
være i aktiv transkripsjon. Når DNA ikke er i transkripsjon er det pakket tett i 
nukleosomer. Resultatene viser at vekstfaktorer kan åpne flere regioner, 
mens hormonene er mer aktive i å lukke dem. Alle hormoner og vekstfaktorer 
viser seg å affekteres av FoxA1 i større eller mindre grad.  
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2	  Abbreviations	  
 
DMEM - dulbeccos modified eagel medium 
FBS - fetal bovine serum 
SFBS - stripped fetal bovine serum 
ER - estrogen receptor 
AR - androgen receptor 
EGF - epidermal growth factor 
EGFR - epidermal growth factor receptor 
Her2 - Heregulin 
Her2R - Heregulin receptor 
PCR - polymerase chain reaction 
FAIRE - formaldehyde assisted isolation of regulatory elements 
EtOH - Ethanol 
NaCl - sodium chloride 
SERM - selectively estrogen receptor modulators 
AI - aromatase inhibitor  
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3	  Introduction	   	  	  
3.1	  The	  normal	  female	  breast	  
 
The female breast consists of mammary gland, a specific type of apocrine 
gland. It consists of about 20 compartments, alveoli. The alveoli are lined with 
milk-secreting cells called cuboidal cells, a type of epithelial cells formed as 
cubes. Myoepithelial cells surrounds the cuboidal cells and together these 
cells are called the lobular cells, creating the lobular gland (Sopel 2010), 
visualized in fig 1. Myoepithelial cells contracts by stimulation of the hormone 
oxytocin leading to lactation through milk ducts to the nipples. The milk duct is 
called lactiferous duct and is lined with epithelial cells surrounded by 
myoepithelial cells (Sopel 2010). Adipose tissue and connective tissue is 
surrounding the lobules and the ducts, and also blood vessels and lymphatic 
vessels. 
 
 
Fig 1: The anatomy of a normal 
breast, visualizing the lobulis and 
the ducts. (American Cancer 
Society 2014)  
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3.2	  Gene	  transcription	  
 
Housekeeping genes are expressed at all times, but a gene that is just 
transcribed when needed is called regulated transcription. Transcription is 
closely regulated by intracellular signals and is a result of extracellular 
signaling.  
 
3.3	  Mitogens	  
 
A mitogen is a substance, like a hormone or a growth factor, which induces 
cell proliferation. Every cell uses receptors to mediate signals from the 
extracellular space to the intracellular space. The specific substance binding 
to their receptor is called a ligand and can be, among others, hormones and 
growth factors. This binding starts a pathway of signal transduction in which 
leads to different results depending on the ligand and receptor. In many cases 
the pathway leads to gene transcription and cell proliferation.  
 
3.4	  The	  Ras-­‐MAP	  kinase	  pathway	  and	  PI3K/Akt/mTOR	  pathway	  
 
The two pathways are both activated by mitogens that controls the cell cycle. 
In a normal cell these signaling pathways are strictly controlled and loss of 
normal signaling is present in all human tumors. Binding of ligand to the 
receptor activates the receptors by cross-phosphorylation and thereby 
activating either MAPK pathway or PI3K pathway. This activation initializes a 
signal transduction pathway leading to the nucleus. Upon signal arrival in 
nucleus the transcription factors are activated and target genes are 
transcribed. In a tumor cells this transcription can imply replication of tumor 
DNA and cell division with an exponential growth potential. 
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3.4.1 The Ras-MAP kinase pathway 
 
The Ras-MAP kinase pathway is the most studied pathway in biology. Ras is 
a small GTPase located in the intracellular side of the plasma membrane, 
anchored by a lipid and relays signals regarding cell survival, proliferation and 
differentiation from receptor tyrosin kinases at the cell surface in to the 
nucleus (Lin et al. 2014). When Ras is activated Raf is recruited to the plasma 
membrane and activated. This activation activates Mek, which activates Erk. 
Activated Erk translocate to the nucleus where it phosphorylate several 
targets proteins, many of them transcription factors. Myc is a gene regulatory 
protein and one of the early genes targeted by Ras. Myc increases the 
expression of several delayed response genes, such as cyclin D1which leads 
to increased G1-Cdk-activity. Activated G1-Cdk will phosphorylate and 
inactivate proteins in the Rb-family, releasing the gene regulatory protein E2F. 
The E2F protein activates transcription of G1/S-genes, including the gene for 
G1/S-cyclin and S-cyclin. Due to this activation, G1/S-Cdk (E-cyclin) and S-
Fig 2: An overview of PI3K/MAPK pathway (Clinical Cancer Research 2014).  	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Cdk (A-cyclin) is produced and promotes additional phosphorylation of Rb-
proteins, making a positive feedback loop. E2F stimulates transcription of its 
own gene, making another positive feedback loop. Activation of cyclin E and 
cyclin A will lead to both DNA synthesis and cell proliferation.  
 
Studies show that Ras is hyperactivated in over 50% of cases of cancer. 
Several signal cascade pathways is dependent of Ras, making Ras an 
oncogene when not regulated properly (Christoffersen 2013; Kleiveland 
2013).  
 
3.4.2 The PI3K/AKT/mTOR pathway 
 
Phosphoinositide 3-kinase (PI3K) binds activated receptor tyrosin kinase 
through Src homology 2 (SH2) interaction domain, activating the kinase.  
PI3K phosphorylates the inositol 3-position of phosphpoinositol resulting in 
PI(3,4,5)P3. PIP3 recruit signaling proteins with a pleckstrin homology (PH) 
domain to the membrane. The signaling proteins are the serine/threonine-
kinases Akt and PDK1. They are both recruited to PIP3 domains through their 
PH-domain. Akt is activated by phosphorylation by PDK1 and mTOR. Akt then 
dissosiates from the membrane and phosphorylates the target protein 
(Christoffersen 2013). 
 
3.5	  Breast	  cancer	  
 
Cells usually undergo apoptosis or cell death after some time, but cancer cells 
avoid this mechanism and keeps reproduce in defiance of the normal restraint 
on cell growth and division creating a tumor. A tumor can be benign, non 
cancerous, or malign, cancerous. Malign tumors can invade nearby tissue and 
metastasize to other parts of the body through lymphatic vessels and the 
blood stream (National Cancer Institute).  
 
Breast cancer is a rapidly growing disease in the western world and is ranked 
as the most common cancer in females (Jemal et al. 2011). It is a 
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heterogenouse disease, aggression and proliferation varying from woman to 
woman (Rouzier et al. 2005) and a genetic abnormality is always the cause 
(Vogelstein & Kinzler 2004). These abnormalities can be inherited (5-10%), 
but most common they arise due to age and environmental factors (85-90%) 
(Breastcancer.org 2013). Breast cancer normally starts in the lobules of the 
breast, the glands producing milk, or the duct (Brisken 2013). Tumors arising 
from the ducts are called ductal carcinomas and are the most common (Keller 
et al. 2012), while tumors arising from the lobules are called lobular 
carcinomas. The first symptoms of breast cancer may be a lump in the breast 
or a change in the nipple shape or position. The smallest tumors, however, 
are only noticeable with mammography, but the screening effect of 
mammography is still debatable. Breast tumors arise from epithelial cells and 
are called carcinomas. The carcinomas are divided according to localization 
and stages. About 75% of breast carcinomas start in the ducts, while 
approximately 25% starts in the lobules. Before the tumor spreads to the 
tissue, it is described as "in situ", meaning it has not invaded the surrounding 
tissue, as shown in fig 3. 
 
 
Fig 3: The development of ductal carcinoma in situ 
(Justoncology.wordpress.com 2011) 
	  	   	   	   	  13	  
When the tumor invades the surrounding tissue, the carcinoma is describes 
as "invasive", as shown in fig 4. 
 
  
 
 
Types of breast cancer are defined according to which receptors that are 
over-expressed by tumor cells. The tumor cells are classified as positive if the 
specific receptor is over-expressed and negative if the tumor cells are not 
over-expressed for a specific receptor. The tumor cell is either endocrine 
receptor (estrogen or progesterone receptor) positive, heregulin (HER2) 
positive, negative for all receptors above (triple negative) or positive for all 
receptors above (triple positive) (Carey et al. 2007).  
 
3.6	  ER	  -­‐	  Estrogen	  receptor	  
 
Estrogen is a steroid hormone and the primary sex hormone in women. It is 
mainly produced in the ovaries and, in small amounts, other parts of the body, 
like fat cells, liver cells adrenal glands and breasts. Estrogen is responsible for 
the normal female development. It is synthesized from cholesterol via 
androstenediol to estradiol, the most potent estrogen, by the enzyme 
Fig 4. About 75% of breast cancers start as ductal carcinomas, while about 25% starts 
as lobular carcinomas. (Community Connect to Research 2012) 
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aromatase.  
 
Estrogen is the ligand for the nuclear receptor, estrogen receptor (ER) which 
acts as a transcription factor to regulate cell division (Hurtado et al. 2011). 
Estrogen binds to estrogen receptor within the cell and the receptors dimerize 
and translocate into the nucleus where the complex binds to estrogen-
responsive elements (ERE) in the DNA. ERE are specific regions in the 
promoters for estrogen target genes. About 75% of breast cancer overexpress 
ER (Dowsett 2001). ER mediates the response of estrogen in mammalian 
cells and starts transcription of target genes (Khan et al. 1998). 
Overexpression of ER leads to increased induction of cell proliferation and the 
most effective treatment is to inhibit the signaling transduction by this nuclear 
receptor.  
 
 Patients with an overexpression of ER have a better outcome with lower rate 
of recurrence within the first several years of treatment (Platet et al. 2004). ER 
is not only correlated to breast cancer, it is also found in normal breast 
epithelial with expression varying throughout the menstrual cycle, but then 
expressed at a normal level (Khan et al. 1998). There are two types of ER, α 
and β. These two are similar in structure and function, but only ERα 
significance in breast cancer is known (Sommer & Fuqua 2001). Estrogen can 
also bind ERβ in which together with GPR30 give a nongenomic responce, 
also shown in fig 2.  
 
3.7	  AR	  -­‐	  Androgen	  receptor	  	  
 
Androgen is a collection of steroid hormones and the primary sex hormone in 
men and is produced in the testis. Women produce testosterone in the 
ovaries.  
 
Like ER the androgen receptor is a ligand dependent transcriptional activator, 
a nuclear receptor, shown in fig 3, (Mehdipour et al. 2011). Its target genes is 
a protein functioning as a steroid-hormone transcriptional factor (NCBI 2014). 
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AR can be present in breast cancer independent of subtype-definition by 
receptors, and is expressed in up to 90% of ER-positive and 55% ER-
negative tumors (Lakis et al. 2014). The prognosis value of AR in ER-negative 
tumors is less clear, but in ER positive cells AR is reported to have an 
inhibitory effect on proliferation 
(Hickey et al. 2012). It is suggested 
that AR occupies similar cis-
regulatory elements as ER, thereby 
inhibiting ER transcription, and data 
analysis support these thesis 
(Robinson et al. 2011). 
 
 
 
 
 
 
 
 
3.8	  Her2-­‐receptor	  	  
 
20-30% of breast cancer tumors are Her2 positive (Sanpaolo et al. 2012). 
Her2 is a oncogene, also called ErbB2, and its receptor is a member of the 
epidermal growth factor receptor (EGFR) family, a receptor tyrosin kinase, 
located at the cell surface (Moasser 2007). Her2-receptor exists initially as 
monomers, but form receptor heterodimers, usually with Her3, upon binding of 
the ligand heregulin. Her2 cannot form homodimers, implying that there is no 
known ligand that directly binds Her2 (Rubin & Yarden 2001). Upon 
dimerization the MAP kinase pathway or PI3K pathway is activated by 
phosphorylation, as shown in figure 6, leading to transcription of genes 
regulating the cell cycle progression, resulting in cell prolifereation. Tumors 
that are positive for Her2 can be treated with monoclonal antibodies, like 
Trastuzumab. These antibodies reduce the growth of the tumor by inhibiting 
Fig 5: The actions of AR 
(Nature.com 2001). 
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Her2 function (Gajria & Chandarlapaty 2011; Sorensen et al. 2013). Although 
these treatments, patients with Her2 positive tumors still have lower overall 
survival rate (Chandarlapaty & Modi 2011; Weigelt et al. 2010).  
 
 
 
 
 
 	  	  
	  
	  
	  
	  
	  
	  
3.9	  EGFR	  -­‐	  EGF-­‐receptor	   
 
EGF receptor is also caller Her1/ErbB1 receptor. The receptor is also a 
tyrosin kinase, located on the cell surface, like the Her2 receptor. EGF 
receptor belongs to the tyrosin kinase family. Unike Her2 receptor, Her1 
receptor homodimerizes upon binding of the ligand EGF. Dimerization is 
necessary for the receptor tyrosin kinases to cross-phosphorylate each other 
by activated kinase domain. This activation starts a cascade of actions, 
phosphorylation-driven signal transduction ending in cell proliferation. EGFR 
is found in, amongst other, breast cells and regulates cell proliferation, 
differentiation and cell survival. Studies have revealed that EGFR is over-
expressed in triple negative breast cancers, showing the importance of 
improving anti-EGFR therapy (Brand et al. 2014). There is also indications of 
Fig 6: Her2R/EGFR and their cascades (Perik et al. 2007) 	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a link between tumor resistance to tamoxifen and increased EGFR expression 
(Moerkens et al. 2014).  	  	  
3.10	  Treatment	  of	  breast	  cancer	  in	  patients	  
 
There are several ways of treating breast cancer and it is often necessary to 
combine treatments. It is important for at treatment plan to reveal as much 
information as possible from the tumor. Triple diagnostics is therefore the first 
step. Triple diagnostic includes a clinical examination, imaging examination, 
mammography and ultrasound, and a needle biopsy (Schlichting 2009). The 
information gathered in these examinations is the background for the 
treatment plan. Sometimes it is desirable to start with radiation to reduce 
tumor size, prior to surgically removal. Depending on the size of the tumor, 
the surgeon will remove the whole breast or just the tumor with tissue around, 
called breast-conserving surgery. Analysis of the removed tissue will reveal if 
it is necessary to remove more of the surrounding tissue. After surgery, the 
treatment is radiation, chemotherapy or hormone therapy, depending on the 
tumor type. In this thesis I will only discuss the hormonal therapy. 
 
The aim of hormonal treatment is to reduce the risk of a new tumor. The 
hormonal treatment of choice will depend on the tumor type, which receptors 
are present in the breast cancer cells. For patients with breast cancer cells 
who are positive for estrogen receptor (ER) the optimal treatment is inhibiting 
the action of estrogen and thereby inhibiting transcription of the genes in 
question. There are two ways of inhibiting estrogen action, beside surgical 
removal of the ovaries, selective estrogen receptor modulators (SERM) and 
aromatase inhibitors (AI). Aromatase is an enzyme that converts androgenic 
hormones to estradiol, as shown in fig 7, the main source of estrogen in 
breast cancer. The treatment depends on whether the woman is 
premenopausal or postmenopausal (Dowsett 2001). Estrogen deprivation in 
premenopausal women will give several unwanted side effects. SERM, like 
Tamoxifen, binds to ER with a higher affinity than estrogen, thereby inhibiting 
binding of estrogen and preventing estrogen response.  
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As previously mentioned, the most effective way of treatment for ER positive 
breast cancer is to stop estrogen response. There are different ways of 
conducting this. Endocrine therapy drugs like tamoxifen and aromatase 
inhibitors are the most common. Patients with Her2 positive tumors can be 
treated with monoclonal antibodies which binds the Her2 receptors,  
 
Cancer therapy can target several of the components of the signal 
transduction pathway. The ligands can be neutrialized before binding to 
receptors, the receptors can be inhibited by binding of antibody or inhibiting 
phosphorylation, intracellular second messengers can be bound by inhibitors 
and nuclear transcriptional factors initializing cell proliferation can be inhibited.  
However, several patients do not respond to these treatments, without an 
obvious reason (Hurtado et al. 2011), implying that it might be other factors 
contributing to these progression. An important discovery for in vitro studies is 
that the extra cellular matrix, and thereby 3D cultures, is necessary for the 
response of treatment for Her2 positive tumors (Weigelt et al. 2010). 
	  	  	  	  
Fig 7: Cholesterol is converted throught several steps, included to progesterone, 
androstenediol and testosterone, until it is converted to estradiol by aromotase (Molecular 
endocrinology 2014).  
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3.11	  MCF-­‐7	  
 
The MCF-7 cell line is a breast cancer cell line derived from a 69-year old 
woman in Detroit. She had breast cancer that metastasized and the MCF-7 
cells were taken from a pleural effusion revealing malignant adenocarcinoma 
(MCF7.com). MCF is abbreviation for Michigan Cancer Foundation and the 
cell line has proven useful for in vitro cancer studies because it still has the 
same properties as mammalian cells (Levenson & Jordan 1997). The MCF-7 
cells are ER positive and AR positive (Osborne et al. 1987). Her2 is 
expressed, but not amplified, thereby characterized as Her2 negative. 
 
3.12	  FoxA1	  
 
FoxA1 is an abbreviation for forkhead box protein A1. The forkhead box 
proteins are transcription factors within DNA-transcription due to their 
"winged-helix" DNA-binding domain (Lam et al. 
2013). They are known to open condensed 
chromatin upon binding, thereby probably 
functioning as pioneer factors (Hurtado et al. 
2011). Many proteins associated with gene 
expression have a specific structural motif, the 
helix-turn-helix (HTH) motif, which is necessary 
for the protein to bind DNA (Alberts et al 2008). 
Between the to α-helices there is a short turn of 
amino acids and flanking this HTH-region are two 
loops ("wings") of polypeptide chains, shown in 
fig 8, making FoxA1 able to bind DNA with high 
affinity at specific sites, as a monomer (Cirillo & Zaret 2007). Cheung and 
Ruan proposed a model in Nature Genetics 43, 2011, supposedly of how 
FoxA1 interacts with the chromatin, presented in fig 9. The illustration shows 
how FoxA1 is supposedly necessary for the binding of estrogen receptor to 
the chromatin, and the end result in this illustration is how no target genes are 
transcribed if FoxA1 is not present. (Cheung & Ruan 2011)  
Fig 8: How FoxA1 is 
assumed to bind DNA 
through "winged shaped" 
helixes (Transcription Factor 
Encyclopedia 2011). 	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Fig 9: The proposed model for the role of FoxA1 in determining ERα-chromatin interactions. 
(Cheung & Ruan 2011) 	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3.13	  Aim	  of	  the	  study	  	  
 
ER+ and AR+ positive tumors are widely represented in all breast cancer 
subtypes. It is necessary for ER/AR to gain access to the open chromatin 
before starting transcription, and it is assumed that FoxA1 is opening the 
chromatin. However, we don't know how different factors contribute to these 
functions, as shown in fig 10. There has been suggested that hormones or 
growth factors controls the expression of genes by influencing the opening of 
the chromatin or that this opening is regulated by a pioneer transcription 
factor.  	  
Hypothesis:  
Hormones or growth factors influence the opening 
of the chromatin. 
 
1. Is the opening of the chromatin regulated by 
 growth factors and/or hormones? 
2. Does FoxA1 open adjacent chromatin under 
different signals?  
 
Due to these questions the design for the experiment were made. First, knock 
down of FoxA1 in half of the plates cultured, then treat the cells with different 
hormones or growth factors, as shown in fig 11, isolate the open chromatin 
with FAIRE technique, as shown in fig 12, and compare the results from 
sequencing.  
 
 
 
Fig 10: How are 
hormones/growth factors 
influencing FoxA1 in opening 
of the chromatin? 	  
Fig 11: Experimental design step 1. Knock down of FoxA1 and treat the cells with hormones/ growth 
factors.   	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Fig 12: Experimental design step 2. FAIRE is a technique that isolates the nucleosome free regions, 
though of as open regions. 	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4	  Materials	  and	  methods 
 
4.1	  Materials	  
 
4.1.1 MCF-7 cell line  
 
The cells were taken fresh from a stock frozen at -170'C. The cells were 
thawed gently and distributed in a flask with 10ml 10% FBS red DMEM 
medium, and incubated at 37'C.  
 
4.1.2 Growth medium 
 
The medium used were phenol red DMEM with FBS to a total concentration of 
10%. Phenol red DMEM is only used before transfection. When the cells were 
prepared for transfection, the medium was changed to clear DMEM added 
glutamax and pyruvat with charcoal stripped FBS to a concentration of 5%. 
When changing the medium 48h after transfection this concentration was 
changed to 2% for the plates supposed to be treated with growth factors and 
remained 5% for the plates supposed to be treated with hormones. The 
phenol red can interference with experiments involving estrogen treatment as 
it mimics estrogen (Berthois et al. 1986). 
 
4.1.3 Treatments 
 
The different treatments were diluted in clear DMEM. R1881 is a synthetic 
androgen, called metyltrienolone. It is the most potent synthetic androgen for 
binding to AR and was added to a total dilution of 1nM the plate for 4 hours. 
Estradiol (E2) is the most potent estrogen for binding to ER. Estradiol were 
added to the plate to a total dilution of 10nM for 1 hour. Vehicle is ethanol, 
added to a total concentration of 10nM to the plate, also for 1 hour. EGF was 
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added for a total dilution of 100ng/ml in the plate, for 90 minutes. Heregulin 
was added to a total concentration of 25ng/ml to the plate for 90 minutes. All 
incubations were in 37'C. 
 
4.1.4 Reagents, buffers and chemicals 	  
For a specific overview of buffers and treatment dilutions, see appendix. 
 
Cell culture      
 clear DMEM (1X) - Dulbeccos Modified Eagel Medium, added 
 glutamine and pyruvat - Life Technologies ™ 
 clear DMEM (1X) - dulbeccos modified eagel medium - Life 
 Technologies ™ 
 red DMEM (1X) - dulbeccos modified eagel medium, with phenolred - 
 Life Technologies ™ 
 FBS - fetal bovine serum - Life Technologies ™ 
 SFBS - charcoal stripped fetal bovine serum - Life Technologies ™ 
 0,25%Trypsin-EDTA (1X) - Life Technologies ™ 
 Optimem - redused serum medium, no phenol red - LifeTechnologies™ 
 Lipofectamine RNAiMAX - invitrogen - Life Technologies™ 
 siRNA - invitrogen - Life Technologies™ 
 siNT - invitrogen - Life Technologies™  
 Formaldehyde, 37% - sigma aldrich 
 Glycine - invitrogen - Life Technologies™ 
 protease and phosphatase inhibitor - Thermo scientific  
 PBS - phosphate buffered saline 
  
Electrophoresis 
 DNAzapp 1 and 2 - ambion Life Technologies™ 
 Tris Acetate-EDTA buffer - TAE (1X) - sigma aldrich 
 Agarose - sigma aldrich 
 SYBR®  gold nucleic acid gel stain - invitrogen - Life Technologies™ 
 1kb plus DNA ladder - invitrogen - Life Technologies™ 
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 Glygerol loading buffer - 50% glycerol and 50% Tris-HCl 
 Bio-rad mini-sub cell gt.  
 Bio-rad power pac basic sets current. 
 
Protein isolation 
 lysis buffer - see table for details 
 NaCl 5M - NaCl from Sigma Aldrich 
 DTT - Life Technologies ™ 
 Bradford solution for protein detection - AppliChem 
 Tecan Infinite f200 pro and the software i-control 1.7 
 
Western blot 
 PBS (1X) 
 Mini-PROTEAN® TGX™ Precast Gels 
 Precision plus protein TM dual color standards - ladder 
 Mini-PROTEAN® Tetra Cell for Mini Precast Gels 
 Bio-rad trans-blot turbo transfer system 
 Trans-blotR Turbo TM Mini PVDF Transfer packs 
 methanol - sigma aldrich 
 TBS-Tween 20 - Thermo Scientific 
 skimmed milk-powder - sigma aldrich 
 anti-FoxA1 - primary mouse antibody - Abcam   
 anti-RPL13a - primary rabbit antibody - Abcam 
 second mouse antibody and second rabbit antibody - Abcam 
 Film for exposure - GE healthcare amersham hyperfilm ™ EacL  
 SuperSignal West Femto - Chemiluminescent Substrate  
 SuperSignal West Pico - Chemiluminescent Substrate 
  
FAIRE 
 Eppendorf tubes 1,5ml  
 PI - Life Technologies ™ 
 DTT - Life Technologies ™ 
 phenol:chloroform:isoamyl alcohol 25:24:1 - sigma aldrich   
 Phase lock gel light - 5 prime 
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 ProteinaseK - ambion, Life Technologies ™ 
 RNase - Quiagen 
 100% EtOH - sigma aldrich 
 Eppendorf thermo mixer c 
 
Quantification 
 Quant-IT buffer - Invitrogen molecular probes - Qubit dsDNA HS buffer 
 Quant-IT dye  - Invitrogen molecular probes - Qubit dsDNA HS reagent 
 Quant-IT standards 0 and 1  - Invitrogen molecular probes - Qubit 
 dsDNA HS 
 Quant-IT assay tubes  - Invitrogen molecular probes 
 Fluorometer - Invitrogen qubit fluorometer 
 
Library preparation 
 MicroPlex Library PreparationTM kit - Diagenode 
 DNA extraction after gel - MinElute Gel Extraction Kit from Qiagen with 
 MinElute spin coloumn from Qiagen 
 Invitrogen dynal bead separator 
 PCR - bio-rad s1000 tm thermal cycler 
  
Pipets  
 Eppendorf research plus 0,5-10ul, 2-20ul,10-100ul, 100-1000ul with 
 VWR filtertips 10ul, 20ul, 100ul, 1000ul. 
 Pipetboy  comfort with stripettes 5ml, 10ml, 25ml, 50ml - Sarstedt 
 maskiner 
 Transferpipettes 1,5ml - Sarstedt 
 
Other equipments 
 Eppendorf tubes 1,5 ml 
 BD Falcon flasks, 250ml and 600 ml 
 BD Falcon petri dishes, 10 cm. 
 Sarstedt tubes 15 ml and 50 ml 
 sonicator - Bioruptur R plus and Bioruptur watercooler from Diagenode 
 Suction - integra vacusafe 
	  	   	   	   	  27	  
 Illuminator - Transilluminator DR-195M 
 Waterbath - Grant GD100 
 Bio-rad molecular imager ChemiDoc XRS imaging system with the 
 software Image Lab3.0.1 
 Agilent 2100 Bioanalyzer  
 Agilent technologies high sensitivity DNA reagents and chips  
 Labgard class II biological safety cabinet 
 Eppendorf centrifuge 5810 
 nuare autoflow ir direct het CO2 incubator 
 Stuart see-saw rocker SSL4 
 Stovall life science - the belly dancer 
 Leica dmil led microscope 
 Bürker chamber for counting cells. 	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4.2	  Methods	  
 
4.2.1 Grow cells 
 
The MCF-7 cells were grown in phenol red DMEM with 10% FBS for 3 days to 
a confluence of about 80%. After this period, the medium was removed and 
the cells were washed with 10ml PBS. The PBS was aspirated. To detach the 
cells from the flask surface 2ml Trypsin EDTA were added. After 5 minutes of 
incubation in 37'C the cell suspension were transferred to a tube, added 10ml 
phenol red DMEM 10%FBS and centrifuged for 5 minutes by 10.000g. The 
cells formed a pellet and the medium was aspirated. The pellet was 
resuspended in 10ml clear DMEM 10%SFBS and 7,5ul transferred to Bürker 
chamber for counting. A Bürker chamber consist of 9 big A squares with inner 
frame. In this experiment 3 A squares were counted and the average was 
used for calculating the number of cells pr ml. 
 
In this experiment there were plated 1.500.000 cells in each plate, in clear 
DMEM 5%SFBS - charcoal stripped FBS. 1ml of cell suspension and 9ml of 
clear DMEM 5%SFBS were added each plate. It is important to avoid phenol 
red DMEM from this point, since the phenol red can mimic the action of 
estrogen, it binds to ER with an affinity of 0.001% of estrogen, and can 
interfere with the results (Berthois et al. 1986). 
  
4.2.2 Reverse transfection - to knock down FoxA1 
 
Transfection of MCF-7-cells is to implement new RNA to the cell, in this study 
short interference RNA - siRNA. 
 
At the first experiment, the cells were transfected in a regular way according 
to common procedure. This turned out not to be a success since the MCF-7 
cells are sticky and it seemed impossible to separate them down to singles. 
The transfection will not be successful if the cells are dimers or more. A 
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reverse transfection will not be so dependant of single cells, some dimers will 
not interfere with the process.  
 
Knock down in 10 cm plates. 1.500.000 cells in each plate. 
14 plates - 2 different transfections, 6 different conditions + 2 for knock down 
controls. Added 1ml Optimem to each plate. Added respectively 20ul siRNA - 
either siFoxA1 or siNT to each 7 plates. Added 43ul Lipofectamine to each 
plate on top of droplet. Mixed gently to hand and left for 40 minutes in 
roomtemperatur before adding 1ml cells in 10ml clear DMEM.  
 
Lipofectamine is a lipidreagent and when mixing it with siRNA they form a 
RNA/lipid complex. When adding the cells to the mix the positively charged 
cation in the complex will bind the negative charged DNA in the cells. The cell 
will take in the complex by endocytic pathway. Within the cell, the complex is 
degraded and the nucleic acid binds the RISC complex resulting in 
degradation of the targeted mRNA (Hammond 2005). 
 
2 days (48h) after transfection the medium was changed into 5% clear DMEM 
for plates that would be treated with hormones and 2% clear DMEM for plates 
that would be treated with growth factors, and knock down control.  
 
 
4.2.3 Treatment of the cells 
 
6 conditions 
Hormones: Estrogen (E2), androgen (R1881) and control (EtOH) 
Growth factors: epidermal growth factor (EGF), Heregulin and control (2% 
clear DMEM). 
 
The estrogen plates were added estradiol to a final concentration of 10nM and 
incubated for 1 hour. Estradiol (E2) is the most potent estrogen for binding to 
ER. The androgen plates were added R1881 to a final concentration of 1nM 
and incubated for 4 hours. R1881 is a synthetic androgen, called 
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metyltrienolone and is the most potent synthetic androgen for binding to AR. 
The heregulin plates were added heregulin to a final concentration of 25ng/ml 
and incubated for 90 minutes. The epidermal growth factor plates were added 
epidermal growth factor to a final concentration of 100ng/ml and also 
incubated for 90 minutes. All the plates were incubated in 37'C.   
 
After treatment the medium were aspirated and crosslinked with formaldehyde 
to a final concentration of 1%, for 7 minutes. The 2 plates for knock down 
control were not crosslinked. The formaldehyde induces DNA-protein- and 
protein-protein crosslinks and is an effective method to bind nucleosome rich 
DNA. This is the key element in isolation the naked DNA, thought of as the 
regulatory elements, which is the basis for the next step called FAIRE. FAIRE 
was performed on all the treated cells after Western Blot of the control-plates, 
to make sure knock down was successful. To quench formaldehyde, 375ul 
glycine 2.5M was added and left in roomtemperatur for at least 5 minutes. The 
fluids were then aspirated and washed with 600ul cold PBS on ice x 3. The 
cells were scraped with500ul cold PBS+PI and collected in tubes prior to 
freeze at -80'C. 
 
 
4.2.4 Protein isolation for Western Blot - knock down control 
 
This step was only executed for the 2 plates functioning as knock down 
control - to make sure knock down of FoxA1 was successful. The pellets were 
resuspended in 400ul lysis buffer and kept 5 minutes on ice. They were 
sentrifuged 2000g for 5 minutes and supernatant was discareded. The pellet 
were resuspended in 87,3ul lysisbuffer and 1,7ul NaCl 5M and the samples 
rotated at 4'C for 1hour. The samples were then sentrifuged at 14.000g for 15 
minutes and the pellet discarded. The supernatant were pipetted into a fresh 
tube. When performing western blot it is important to load the same amount of 
protein in each lane to be able to see if there is a difference of expression. 
Due to this, the protein amount was quantified with Bradford assay at 450nm. 
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4.2.5 Western blot  
 
It is important to denaturate the proteins before loading the samples on to the 
gel. If the proteins are in its nature state, they will not be able to move through 
the gel. To denaturate the sample it is necessary to boil the samples at 95'C 
for 5 minutes, just prior to loading. 20ug protein pr sample + dual color ladder 
were loaded and the gel ran at 100V for about 1hour, until the dual color 
marks started to move out at the bottom. The gel chamber was opened and 
the proteins in the gels was blotted to PVDF membrane, using a Bio-rad 
trans-blot turbo transfer system.  
 
The PVDF membrane is very hydrophobic and needs to be activated with 
methanol to gain full binding capacity to proteins. After methanol activation the 
PVDF membrane were shaked in 2% skimmed milk for 1hour in room 
temperature. The skimmed milk is necessary for its protein contents. The 
PVDF membrane binds proteins unspecific, and as the antibodies used to 
detect the proteins we are looking for in itself is proteins, they will bind the 
membrane as well as the desired proteins. The skimmed milk proteins bind to 
the PVDF membrane, leaving no other room for the antibodies to bind but the 
desired proteins.  
 
The membrane contains to different proteins of interest, 
the FoxA1-proteins and the loading control, RPL13a-
proteins. It is necessary to cut the membrane in two in 
order to add the right antibody to the right part. The 
membrane was cut at 75 kD mark and 25 kD mark. FoxA1 
is around 50 kD. The part of the membrane under 25 kD 
mark contain the ribosomal protein, RPL13a. 
6ml of first antibody solution were made for each, in 
dilution 1:500. 12ul of antibody were added to 6ml of 
skimmed milk. The FoxA1 part of the membrane was 
added the mouse first antibody and the RPL13a rabbit 
Fig 13: kD marks of precision plus 
protein dual color ladder. 
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first antibody. The membrane with the antibodies was left over night in 4'C on 
a tilter. 
 
The antibodies can be used several times, so they were recovered by 
pipetting and transferred back to the Falcon tube. The membranes were 
washed 3 times with TBS tween, 10 minutes each wash, to remove excess 
antibodies. Secondary antibodies were added, in dilution 1:20.000 in 5ml 
skimmed milk, and left on shaker in room temperature for 1h. The secondary 
antibodies were removed and TBS tween were added for washing 4 times 
within an hour. 
 
To see the bands a developing technique was used. In the dark room a 
solution of Femto were added to the FoxA1 membrane and a solution of Pico 
were added to the RPL13a membrane. The Femto is highly more sensitive 
than Pico, detecting low femtograms amounts of protein (Thermo Scientific). 
The Kodak R developing film was exposed to the membrane for different 
timepoints, to find the optimal time for exposure, 1 min, 30 sec, 20 sec, 10 
sec, 5 sec and 2 sec. After development, the section containing the RPL13a 
will show if the same amount of protein is loaded in both lanes and if the 
knock down of FoxA1 was success.  
 
 
4.2.6 FAIRE 
 
FAIRE is abbreviation for formaldehyde-assisted isolation of regulatory 
elements, the part of the DNA that is active at the specific timepoint (Gilfillan 
et al. 2012). Studies confirm that DNA isolated with this approach 
corresponds to active regulatory regions (Giresi et al. 2007).  
 
The pellets were resuspended in 250ul lysisbuffer and sonicated in waterbath 
sonicator for 15 mins. During the sonication the DNA ruptures and the naked 
DNA, though of as the regulatory elements, breaks away from the complexes 
	  	   	   	   	  33	  
made under crosslinking. After sonication the samples were centrifuged at 
14.000rpm for 15mins at 4 'C. The DNA is more stable at this temperature. 
 
An input control of 5ul was taken out before the phenol chlorophorm 
extraction. The same amount of phenol chloroform as sample were added, 
the solution vortexed and transferred to a phase lock tube before 
centrifugation for 5 minutes at 11.000rpm room temperature. The phase lock 
tube separates the organic phase from the aqueous phase with a gel and 
thereby eliminates contamination of interphase proteins (5 PRIME). The 
phenol chloroform extraction and centrifugation were repeated 3 times and 
the product of the extraction, the naked DNA, was put on ice. To remove any 
residues of RNA, the samples were treated with 1ul RNase, ribonuclease, to 
every 100ul sample for 40 minutes in 37'C. RNase is an enzyme that 
degrades RNA. After treatment with RNase, the samples were added 
proteinase K, 1ul to every 100ul sample and put in waterbath for 16 hours to 
decrosslink. The proteinase K inactivates the RNase and degrades any left 
proteins, while decrosslinking is to remove any covalent interactions still 
present after the crosslinking.  
 
The sample was then spun down and DNA precipitated with NaCl to a final 
concentration of 200mM and 100% ethanol. 1ul glycogen was added to the 
sample as well. Glycogen binds DNA and makes the DNA pellet visible. The 
DNA amount is so low that no pellet is visible without glycogen. Cold EtOh 
100% was added as last, double amount as sample before the samples was 
left for 30 minutes in -80'C for precipitation. DNA precipitates in the 
combination of NaCl and ethanol. After precipitation the NaCl is removed. The 
samples are first centrifuged, supernatant discarded and new cold EtOH is 
added. After a new round of centrifugation, the supernatant is removed and 
the pellet air-dried. The NaCl is now removed and the DNA is resuspended in 
warm Tris-HCl, a weak buffer. The samples are kept on ice and frozen in  
- 20'C. 
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4.2.7 Quantification 
 
The quantification of DNA is done with Qubit and will tell how successful the 
experiment was by measuring the difference between the input control and 
the FAIRE product. The measurement with Qubit is calculated from a 
standard curve which is made with the standards 0 and 1 prior to 
measurements with the samples. The measure is photometric. The measuring 
mix is made with 199ul Quant-IT buffer and 1ul Quant-IT dye. The samples 
were diluted in the mix, 199ul of mix and 1ul sample. The standards, 0 and 1, 
were diluted in 190ul mix and 10ul standard. 
 
 
 4.2.8 Electrophoresis 
 
After confirming successful FAIRE experiment the DNA were separated by 
bandsize using electrophoresis. The agarosegel was made as high as 2% to 
be able to distinguish between the smaller molecules. SYBR gold were used 
as fluorescent stainer as it is far more sensitive than Ethidium Bromide and 
proved to be a good choice as the DNA product was very small. The ladder 
used was 1kb. To avoid smear, and then misinterpretation of the bands,  from 
the regular blue loading dye, a loading buffer with 50% glycerol and 50% Tris-
HCl was made. 12ul of sample was mixed with 3.58ul of the glycerol loading 
buffer. During loading it was only possible to see a change of light fraction 
where the samples were loaded. The gel was run at 30V for 3 hours as a 
lower voltage separates the bands better. After the run the 200kb bands were 
cut, approximately at 150kb and 250kb, on a trans illuminator, and purified 
with Gel Extraction kit. The eluted DNA was quantified again. 
 
 
4.2.9 Library preparation 
 
DNA library were made with the use of a library preparation kit and PCR. The 
steps in library preparation are template preparation, library synthesis, library 
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amplification with indexing and library purification.  The libraries were 
quantified and the bands controlled in Bioanalyzer, making sure there was 
only 1 peak in each lane. 
 
 
4.2.10 Sequencing 
 
The samples were prepared for sending for high throughput sequencing at 
Beckman in Chicago, USA, and was made as 20ul containing 10ug DNA/ul. 
The sequencing was performed with Illuma HiSeq. 2000.  
 
 
4.2.11 Data analysis 
 
The data analysis is based on the idea that the open regions are 
transcriptional regions and the more open regions at the same location, in all 
the samples submitted, the higher the level of transcription. By comparing 
these regions in different conditions/treatments it will be visible which 
condition/treatment results in a higher rate of transcription.   
 
The results from sequencing were analyzed using scripts made by the 
University of Oslo. The sequencing file from the control and the sequencing 
file from the treatment were analyzed the same way until they were compared 
in Galaxy. The files were aligned with hg19, which is the most updated 
database for the humane genome, using Bowtie and then sorted before 
removal of duplicates. The numbers of duplicates in the samples were low, 
ranging from 9,4% to 22,3% with the average at 15,4%. Then, peak calling 
with MACS and normalizing with a MCF-7-file. When normalizing with MCF-7-
input file, the peaks become visible. These peak-files were sorted by "lost" 
(A), "common" (B) and "gained" (C) regions using Galaxy, an "open source, 
web-based platform for data intensive biomedical research." (Galaxy). Galaxy 
made it possible to find overlapping regions to calculate numbers of each 
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region, and to sort them into common, lost and gained regions. First step was 
to find the overlapping region of at least 1 basepair between two individual 
treatments. This is the common region (B). Then, subtract the common region 
from the control. This is the region lost by treatment (A). At last, subtract the 
common region from the treatment. This is the regions gained by treatment 
(C).  
 
The files were also compared to its wild type, meaning the knock down 
(siFoxA1) file in one treatment was compared to the control (siNT) file in the 
same treatment. By these comparisons it was possible to see the difference 
between conditions, and treatments.
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5	  Results	  	  
 
The first interesting result was to see if knock down 
of FoxA1 was a success. As seen in fig 14 the lane 
loaded with siNT sample have much stronger bands 
than the lane loaded with siFoxA1. The amount of 
proteins loaded was the same in both lanes, as 
seen in the loading control RPL13a, so any 
difference in the result is due to different expression.  
 
 
 
 
 
 
Fig 14: Knock down of FoxA1 
was successful. 
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Results	  by	  treatment:	  
Estrogen (estradiol, E2) 
 
 
 
 
 
The cells treated with estrogen were grown in clear DMEM with 5%SFBS after 
the medium was changed, 2 days after transfection. The stimulation time for 
the treatment was 60 minutes. 
 
As seen in the venn diagram where FoxA1 is not knocked down, there is a 
small opening of about 50.000 sites when the cells are treated with estrogen, 
compared to the control. 50.000 sites are only 18% of all the treated regions, 
not enough to be sure its not background.  
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Fig 15: Comparison between which sites are lost by treatment, which are common with treatment and 
which are gained. The samples displayed as a venn diagram are the open regions with treatment and 
without (control). FoxA1 has not been knocked down.	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As seen on the venn diagram the sites closing are 130.000 which is 35% of 
the original sites. It seems like estrogen have an stronger action for closing 
regions, than opening new.  
 
The common sites are 240.000, 65% of the original sites.  
 
When comparing the siNT to the siFoxA1 we see that less sites are closing in 
the control when knocking down FoxA1, implying that FoxA1 is necessary to 
keep the regions open. For the opening sites it seems like the activity is 
dependant of FoxA1, event thought it is a small number.  
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Androgen (methyltrienolone, R1881) 
 
	   
 
 
 
The cells treated with androgen were grown in clear DMEM with 5%SFBS 
after the medium was changed, 2 days after transfection. The stimulation time 
for the treatment was 4 hours. 
 
The venn diagram shows that when the cells were treated with synthetic 
androgen, methyltrienolone (R1881), there was an opening of about 90.000 
new sites with 25% of the treated area was unique for androgen.  
 
Of the control sites 70% of the sites were common with the treated sites. 
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Fig 16: Comparison between which sites are lost by treatment, which are common with treatment and 
which are gained. The samples displayed as a venn diagram are the open regions with treatment and 
without (control). FoxA1 has not been knocked down. 
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110.000 sites were lost compared to the cells treated with androgen. 
 
When comparing the siNT to the siFoxA1 the activity of androgen in gained 
and lost sites are dependant of FoxA1. 
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Epidermal growth factor (EGF) 
 
 
	  
 
 
The cells treated with EGF were grown in clear DMEM with 2%SFBS after the 
medium was changed, 2 days after transfection. The stimulation time for the 
treatment was 90 minutes. 
 
As seen in the venn diagram EGF is able to open several new regions the 
control is not able to. When comparing the control to the EGF-treated regions 
EGF opens 140.185 new sites to a total of 240.000, with 41% of the sites 
common. 76% of the original sites were common. EGF is able to close more 
regions when FoxA1 is absence, than when FoxA1 is present. 
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Fig 17: Comparison between which sites are lost by treatment, which are common with treatment and 
which are gained. The samples displayed as a venn diagram are the open regions with treatment and 
without (control). FoxA1 has not been knocked down. 
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When comparing the siNT to the siFoxA1 the amount of active regions are 
higher in the gained regions treated with siNT, than in the regions where 
FoxA1 were knocked down. The activity of EGF is not fully dependant of 
FoxA1, but seem to be affected in some way. The activity is lower when 
FoxA1 is knocked down, but not as low as for the control. For the common 
sites, the control is affected by FoxA1, but not EGF.  
 
The control sample seems to be dependant of FoxA1 to keep the regions 
opened.  
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Heregulin (Her2) 
 	  
	  
	  
The cells treated with heregulin were grown in clear DMEM with 2%SFBS 
after the medium was changed, 2 days after transfection. The stimulation time 
for the treatment was 90 minutes. 
 
As the venn diagram shows heregulin is able to open several new regions, 
even more than EGF. Heregulin opens 290.000 unique new sites to a total of 
390.000. The common sites are only 25% of the total treated sites, while the 
common sites compared to the original sites are 77%.  
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Fig 18: Comparison between which sites are lost by treatment, which are common with treatment and 
which are gained. The samples displayed as a venn diagram are the open regions with treatment and 
without (control). FoxA1 has not been knocked down. 
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The cells treated with the growth factor heregulin were able to open more 
regions independent of FoxA1. Heregulin is not affected by the absence of 
FoxA1, as EGF is. When FoxA1 is knocked down, heregulin is able to close 
more regions. It seems that the control sample is dependent of FoxA1 to keep 
the regions opened, like for EGF.  
 
It is important to remember, when comparing the number of regions for growth 
factors to the control the control plates for the growth factors are grown in 2%, 
not 5% like for the hormone control. This will influence the growth of the 
control cells and might give a false low amount of regions. It should not 
influence as much, since the cells treated with growth factors are grown in the 
same percentage medium, but the difference in the overall picture, where the 
hormones are compared to the growth factors in opening and closing of the 
regions, might be affected. 
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The overview off all the sites opening under treatment shows that the growth 
factors are more active in opening the chromatin than the hormones. This 
observation corresponds to the individual results, the growth factors EGF and 
heregulin are able to open several more sites than the hormones, with more 
unique sites for the growth factors, only 13.000 sites common between EGF 
and androgen, and 15.000 common sites between heregulin and estrogen. In 
total, the growth factors opens 252.000 sites unique for growth factors, while 
the hormones opens 84.000 sites unique for hormones.   
 
Fig 19: An overview of all the open regions in cells transfectet with siNT, FoxA1 has not 
been knocked down. The figure shows the result of the treatment with hormones and 
growth factors, comparing how many regions are open and how many are common. 
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The overview of the all the lost sites under treatment shows that the 
hormones are more active in closing the chromatin than the growth factors. 
This observation also corresponds to the result displayed by individual 
treatments showing that the hormones are more active in closing the regions 
than the growth factors. Together, the hormones closes 132.500 sites unique 
to the hormones, while the growth factors closes 31.000 sites unique to the 
growth factors.  
 
Fig 20: An overview of all the lost regions in cells transfectet with siNT, FoxA1 has not 
been knocked down. The figure shows the result of the treatment with hormones and 
growth factors, comparing how many regions are gained and how many are common. 
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6	  Discussion	  	  	  	  
Studies have shown that MCF-7 cells with overexpression of Her2 are 
hyperactivated in the MAPK pathway and also resistant to antiestrogen 
treatment (Kurokawa & Arteaga 2003; Lupien et al. 2010) and this would 
explain why as much as 30% of breast cancer patients have a poor response 
to endocrine treatment. It is not uncommon to develop resistance to SERM 
after some time of treatment (Schiff et al. 2003). In addition, a study of long 
term estrogen depletion of MCF-7 cells (LTED) show that these cells have a 
higher level of ERα and a higher level of type I tyrosin kinase growth factor 
signalling in vitro (Martin et al. 2005). It might be due to adaptation to 
environmental factors and could have the same effect in vivo. These cells also 
show increased MAPK activity (Kurokawa & Arteaga 2003). It is possible that 
this is the reason why patients develop resistance to anti-estrogen therapy 
over time. Martin et al also have results that implies that the cell can adapt to 
different pathways to counter deprivation of a substance (Martin et al. 2005)  
 
For the hormone treated cells in this study there is a small difference in 
opening of unique regions between androgen and estrogen, but how big this 
difference is can be debatable. The opening is affected by FoxA1 in both 
treatments. The overall comparison between the siNT hormones shows that 
most of the regions are overlapping, which means that most of the regions 
induces by estrogen or androgen is shared. 
 
The growth factors have a strong influence in opening the chromatin, but not 
in closing. Heregulin have a much stronger action than EGF in opening, and 
they are both independent by FoxA1, EGF more than heregulin. Heregulin 
seems to open the chromatin and allow the function of Foxa1. This 
independence by the growth factors together with the fact that the cell can 
alter which pathway to use due to environmental factors might be the reason 
why patients with tumors positive for her2 have such bad prognosis.  
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Conclusion 
Both experiment for growth factors shows a strong action in opening the 
chromatin, heregulin stronger than EGF. This opening is affected by FoxA1 to 
some extend, but not dependent. Heregulin seems to open the chromatin and 
allow the function of Foxa1. FoxA1 seems to be necessary to keep the 
chromatin open in cells treated with growth factors, as the closing of the 
chromatin is higher among the controls when FoxA1 is knocked down. The 
hormon treatment experiment shows that the opening of regions are low and 
more affected by FoxA1. The closing of the original regions however is higher 
in both hormon experiment and also strongly affected by FoxA1. This implies 
that the hormones have a strong action in closing regions, while the growth 
factors have a strong action in opening regions. From my result, it is not 
possible to conlcude that these actions are dependent of FoxA1 as there still 
is a level of transcription when FoxA1 is knocked down. From the western 
blot-result some small parts of the protein is still visible, and maybe it is 
enough to have a function? What I can conclude is that growth factors have 
the ability to open chromatin and that these chromatin remodelling actions are 
affected by FoxA1, the hormones more than the growth factors.  
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Appendix	  1	  -­‐	  table	  for	  treatments	  and	  solutions	  	  
Treatment of the cells 
Treatment Dilution  Apply to 
sample 
Incubation 
time 
Androgen 
(R1881) 
1:1000 999ul medium + 1ul R1881 
Final conc: 1nM 
1ul 4h 
Estradiol 
(E2) 
1:100 99ul medium + 1ul E2 
Final conc: 10nM 
10ul 1h 
Vehicle 
(ethanol) 
1:100 99ul medium + 1ul ethanol 
 
10ul 1h 
EGF 1:100 297ul medium + 3ul EGF 
Final conc: 100ng/ml 
100ul 90 mins 
Heregulin 1:20 228ul medium + 12ul 
Heregulin 
Final conc: 25ng/ml 
100ul 90 mins 
 
Lysisbuffer for western blot 
Lysis buffer for enrichment of Nuclear fraction  
Final cons Stock Making 10ml 
20mM Hepes 1m Hepes pH 7,7 200ul 
10mM NaCl 5M 20ul 
1,5mM MgCl 1M 15ul 
20% Glycerol 40 % 5ml 
0,1%TritonX-100 10 % 100ul 
1mM DTT 1M  For 4ml: 4ul 
Thermo Scientific Proteinase & Phosphatase for 4ml: 40ul 
 
PBS 
Salt Concentration (mmol/L) Concentration (g/L) 
  NaCl   137 8.0 
  KCl   2.7 0.2 
  Na2HPO4   10 1.44 
  KH2PO4   1.8 0.24 
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